Caladrius Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Caladrius Biosciences's estimated annual revenue is currently $9.8M per year.
- Caladrius Biosciences's estimated revenue per employee is $155,000
Employee Data
- Caladrius Biosciences has 63 Employees.
- Caladrius Biosciences grew their employee count by 5% last year.
Caladrius Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP R&D and CMO | Reveal Email/Phone |
2 | EVP R&D and CMO | Reveal Email/Phone |
3 | Director Clinical Affairs and Apheresis | Reveal Email/Phone |
4 | Director Clinical Affairs and Apheresis | Reveal Email/Phone |
5 | Staff Accountant | Reveal Email/Phone |
6 | Staff Accountant | Reveal Email/Phone |
Caladrius Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is Caladrius Biosciences?
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.
keywords:N/A
N/A
Total Funding
63
Number of Employees
$9.8M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Caladrius Biosciences News
2022-04-17 - Caladrius Biosciences (NASDAQ:CLBS) Receives New ...
Caladrius Biosciences (NASDAQ:CLBS) Receives New Coverage from Analysts at StockNews.com. Posted by admin on Apr 20th, 2022.
2022-04-13 - Caladrius Biosciences (NASDAQ:CLBS) & Marpai (NASDAQ ...
Caladrius Biosciences (NASDAQ:CLBS) & Marpai (NASDAQ:MRAI) Head-To-Head Comparison. Posted by admin on Apr 15th, 2022.
2022-04-06 - Caladrius Biosciences Treats First Patient in the Phase 1b ...
Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease.
Other Companies in Basking Ridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.5M | 71 | 3% | N/A |
#2 | $7.5M | 72 | -4% | N/A |
#3 | $13.6M | 72 | N/A | N/A |
#4 | $19.1M | 73 | -21% | N/A |
#5 | $4.9M | 74 | -13% | $145.5M |